Advertisement

Incidence of Reye's syndrome in France

A hospital-based survey

      Abstract

      At the time of the study no information was available in France about the incidence of Reye's Syndrome (RS) and no warnings about RS and aspirin. The objective was to evaluate the incidence of RS in France by a hospital-based study. For a period of 1 year from November 1995 to November 1996, all French paediatric departments were required to report any child under 15 years with unexplained noninflammatory encephalopathy (i.e., CDC consciousness level stage I or deeper with normal CSF) and a threefold (or greater) increase in serum aminotransferase and/or ammonia. All suspected cases were classified by a panel of experts as probable RS or excluded RS. In 10% of randomly selected paediatric departments we checked that every suspected case had been reported. Forty-six suspected cases were reported during the year of the survey, of which 14 were classified as RS. Five of these 14 cases had a metabolic disorder. Nine children were definitively diagnosed as having RS (i.e., an estimated incidence of RS of 0.79/1,000,000 children, i.e., below 15/year). Eight children had been exposed to aspirin, four to aspirin alone and four to aspirin and acetaminophen. On the basis of these results the incidence of RS in France in 1996–1997 was not substantially different from that of countries where warning labels were already in use, but it was higher than in the US after 1994. This was probably due to the reduction in aspirin prescription in France because of warnings in Europe and the US and also because many cases of RS are now identified as metabolic disease. On the basis of these results and because the relationship between aspirin and RS has already been proved, public and professional warnings concerning RS on aspirin-containing products in cases of varicella and viral febrile illness have been adopted by the French Drugs Agency.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Epidemiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Reye R.D.K.
        • Morgan G.
        • Baral J.
        Encephalopathy and faty degeneration of the viscera.
        Lancet. 1963; 2: 749-752
        • Halpin T.J.
        • Holtzhauer F.J.
        • Campbell R.J.
        • Hall L.J.
        • Correa-Villasenor A.
        • Lanese R.
        • Rice J.
        • Hurwitz E.S.
        Reye's syndrome and medication use.
        JAMA. 1982; 248: 687-691
        • Starko K.M.
        • Ray C.G.
        • Dominguez L.B.
        • Stromberg W.L.
        • Woodall D.F.
        Reye's syndrome and salicylate use.
        Pediatrics. 1980; 66: 859-864
        • Waldman R.J.
        • Hall W.N.
        • McGee H.
        • Van Amburg G.
        Aspirine as a risk factor in Reye's syndrome.
        JAMA. 1982; 247: 3089-3094
        • Hurwitz E.S.
        • Barett M.J.
        • Bregman D.
        • Gunn W.J.
        • Schonberger L.B.
        • Fairweather W.R.
        • Drage J.S.
        • Lamontagne J.R.
        • Kaslow R.A.
        • Burlington B.
        • Quinnan G.V.
        • Parker R.A.
        • Phillip S.K.
        • Pinsky P.
        • Dayton D.
        • Dowdle W.R.
        Public Health Service study on Reye's syndrome and medications. Report of the pilot phase.
        N Engl J Med. 1985; 313: 849-857
        • Hurwitz E.S.
        • Barett M.J.
        • Bregman D.
        • Gun W.J.
        • Pinsky P.
        • Schonberger L.B.
        • Drage J.S.
        • Kaslow M.J.
        • Burlington B.
        • Quinnan G.V.
        • Lamontagne J.R.
        • Fairweather W.R.
        • Dayton D.
        • Dowdle W.R.
        Public Health Service study of Reye's syndrome and medications. Report of the main study.
        JAMA. 1987; 257: 1905-1911
        • Forsyth B.W.
        • Horwitz R.I.
        • Acampora D.
        • Shapiro E.D.
        • Viscoli C.M.
        • Feinstein A.R.
        • Henner R.
        • Holabird N.B.
        • Jones B.A.
        • Karabelas A.D.E.
        • Kramer M.S.
        • Miclette M.
        • Wells J.A.
        New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association.
        JAMA. 1989; 261: 2517-2524
        • Hall S.
        • Glickman M.
        The British Paediatric Surveillance Unit.
        Arch Dis Child. 1988; 63: 344-346
        • Hall S.
        • Bellman M.
        Reye's syndrome in the British isles.
        BMJ. 1984; 288: 548-550
        • Newton L.
        • Hall S.M.
        Reye's syndrome in the British Isles.
        Communiable Dis Rep. 1993; 3: R11-R16
        • Hurwitz E.S.
        The changing epidemiology of Reye's Syndrome in the United States.
        JAMA. 1988; 260: 3178-3180
        • Arrowsmith J.B.
        • Kennedy D.L.
        • Kuritsky J.N.
        • Faich G.A.
        National patterns of aspirin use and Reye syndrome reporting, United States, 1980 to 1985.
        Pediatrics. 1987; 79: 858-863
        • Centers for Disease Control
        Reye Syndrome Surveillance—United States, 1989.
        MMWR. 1991; 40: 88-90
        • Centers for Disease Control Reye Syndrome Surveillance—United States, 1987 and 1988
        MMWR. 1989; 38: 325-327
        • Belay E.D.
        • Bresee J.S.
        • Holman R.C.
        • Kahn A.S.
        • Shahriai A.
        • Schonberger L.B.
        Reye's syndrome in the United States from 1981 through 1997.
        N Engl J Med. 1999; 340: 1377-1382
        • Treem W.R.
        • Witzleben C.A.
        • Piccoli D.A.
        Medium-chain and long-chain acylCoA dehydrogenase deficiency.
        Hepatology. 1986; 6: 1270-1278
        • Gauthier M.
        • Guay J.
        • Lacroix J.
        • Lortie A.
        Reye's syndrome—a reappraisal of diagnosis in 49 presumptive cases.
        Am J Dis Child. 1989; 143: 1181-1184
        • Saudubray J.M.
        • Charpentier C.
        Clinical phenotypes.
        in: Scriver C.R. Beaudet A.L. Sly W.S. Valle D. The metabolic and molecular bases of inherited diseases. 7th ed. McGraw-Hill, New York1995: 327-400
        • Rashed M.S.
        • Ozand P.
        • Bucknall M.P.
        • Little D.
        Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry.
        Pediatr Res. 1995; 38: 324-331
        • Kimura A.
        • Yoshida I.
        • Yamashita F.
        Necessity of liver biopsy for accurate diagnosis of Reye's syndrome.
        J Pediatr Gastroenterol Nutr. 1987; 6: 153-155
        • Maison P.
        • Guillemot D.
        • Vauzelle-Kervroedan F.
        • Balkau B.
        • Sermet C.
        • Thibult N.
        • Eschwege E.
        Trends in aspirin, paracetamol and non-steroidal anti-inflammatory drug use in children between 1981 and 1992 in France.
        Eur J Clin Pharmacol. 1998; 54: 659-664
      1. Divry P. The relationship of inborn errors of metabolism to Reye's and Reye-like syndromes. In: GR Fryers Aspirine Towards 2000. Royal Society of Medecine Services International Congress and Symposium Series No. 168, London, Royal Society of Medecine Servs Limited, 1990.

        • Orlowski J.P.
        Whatever happened to Reye's syndrome? Did it every really exist?.
        Crit Care Med. 1999; 27: 1674-1676
        • Saudubray J.M.
        • Martin D.
        • de Lonlay P.
        • Touati G.
        • Poggi-Travert F.
        • Bonnet D.
        • Jouvet P.
        • Boutron M.
        • Slama A.
        • Vianey-Saban C.
        • Bonnefont J.P.
        • Rabier D.
        • Kamoun P.
        • Brivet M.
        Recognition and management of fatty acid oxidation defects.
        Inherit Metab Dis. 1999; 22
        • Millington D.S.
        • Terada N.
        • Chace D.H.
        • Chen Y.T.
        • Ding J.H.
        • Kodo N.
        • Roe C.R.
        The role of tandem mass spectometry in the diagnosis of fatty acid oxidation disorders.
        in: Coates P.M. Tanaka K. New developments in fatty acid oxidation. Progress in clinical and biological research. Wiley-Liss, New York1992: 339-354